Dynamic Technology Lab Private Ltd purchased a new stake in Quest Diagnostics Inc (NYSE:DGX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 14,202 shares of the medical research company’s stock, valued at approximately $1,532,000.

Other institutional investors have also recently bought and sold shares of the company. Captrust Financial Advisors grew its stake in shares of Quest Diagnostics by 120.0% in the 2nd quarter. Captrust Financial Advisors now owns 2,712 shares of the medical research company’s stock valued at $298,000 after buying an additional 1,479 shares during the period. Summit Global Investments grew its stake in shares of Quest Diagnostics by 47.7% in the 2nd quarter. Summit Global Investments now owns 41,186 shares of the medical research company’s stock valued at $4,528,000 after buying an additional 13,292 shares during the period. Palo Capital Inc. grew its stake in shares of Quest Diagnostics by 16.4% in the 3rd quarter. Palo Capital Inc. now owns 13,912 shares of the medical research company’s stock valued at $1,501,000 after buying an additional 1,965 shares during the period. Argent Trust Co purchased a new stake in shares of Quest Diagnostics in the 2nd quarter valued at approximately $2,740,000. Finally, HPM Partners LLC purchased a new stake in shares of Quest Diagnostics in the 2nd quarter valued at approximately $272,000. 86.26% of the stock is owned by institutional investors and hedge funds.

Shares of DGX stock opened at $87.56 on Friday. The company has a current ratio of 1.15, a quick ratio of 1.09 and a debt-to-equity ratio of 0.63. Quest Diagnostics Inc has a one year low of $85.56 and a one year high of $116.49. The company has a market capitalization of $12.09 billion, a PE ratio of 16.21, a P/E/G ratio of 1.86 and a beta of 0.89.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Tuesday, October 23rd. The medical research company reported $1.68 EPS for the quarter, hitting the consensus estimate of $1.68. Quest Diagnostics had a net margin of 11.30% and a return on equity of 15.71%. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same period in the prior year, the business posted $1.38 EPS. The business’s revenue for the quarter was up 1.8% compared to the same quarter last year. Equities analysts expect that Quest Diagnostics Inc will post 6.36 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 30th. Stockholders of record on Tuesday, January 15th will be issued a $0.53 dividend. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a dividend yield of 2.42%. The ex-dividend date of this dividend is Monday, January 14th. Quest Diagnostics’s dividend payout ratio is currently 37.04%.

Several analysts have recently weighed in on the stock. Citigroup dropped their price target on shares of Quest Diagnostics from $112.00 to $104.00 and set a “neutral” rating for the company in a research note on Wednesday, October 24th. Argus set a $120.00 price target on shares of Quest Diagnostics and gave the company a “buy” rating in a research note on Friday, September 14th. ValuEngine cut shares of Quest Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, November 30th. Credit Suisse Group increased their price target on shares of Quest Diagnostics from $121.00 to $128.00 and gave the company an “outperform” rating in a research note on Monday, September 24th. Finally, Canaccord Genuity dropped their price target on shares of Quest Diagnostics from $118.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, October 24th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $106.19.

WARNING: “Dynamic Technology Lab Private Ltd Acquires New Position in Quest Diagnostics Inc (DGX)” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/dynamic-technology-lab-private-ltd-acquires-new-position-in-quest-diagnostics-inc-dgx/2669768.html.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Featured Article: How dollar cost averaging works

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.